Walvax BioTech (300142) - Cash Flow Conversion Efficiency

Latest as of September 2025: -0.003x

Based on the latest financial reports, Walvax BioTech (300142) has a cash flow conversion efficiency ratio of -0.003x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥-33.52 Million ≈ $-4.91 Million USD) by net assets (CN¥10.94 Billion ≈ $1.60 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 300142 net asset quality index to measure how much of total assets are equity-financed.

Walvax BioTech - Cash Flow Conversion Efficiency Trend (2007–2025)

This chart illustrates how Walvax BioTech's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check 300142 operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.

Walvax BioTech Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Walvax BioTech ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Hypera S.A SA:HYPE3	0.014x
Par Pacific Holdings Inc NYSE:PARR	-0.107x
Brederode LSE:0QWB	0.004x
Nuscale Power Corp NYSE:SMR	-0.284x
Ebro Foods MC:EBRO	0.071x
SEB SA UNSP.ADR EO-01 F:GRB0	N/A
BKV Corporation NYSE:BKV	0.034x
Centuri Holdings, Inc. NYSE:CTRI	-0.040x

Annual Cash Flow Conversion Efficiency for Walvax BioTech (2007–2025)

The table below shows the annual cash flow conversion efficiency of Walvax BioTech from 2007 to 2025. For the full company profile with market capitalisation and key ratios, see Walvax BioTech market capitalisation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	CN¥9.81 Billion ≈ $1.44 Billion	CN¥494.37 Million ≈ $72.34 Million	0.050x	-44.07%
2024-12-31	CN¥11.51 Billion ≈ $1.68 Billion	CN¥1.04 Billion ≈ $151.68 Million	0.090x	-9.47%
2023-12-31	CN¥11.40 Billion ≈ $1.67 Billion	CN¥1.13 Billion ≈ $165.91 Million	0.099x	-8.99%
2022-12-31	CN¥10.99 Billion ≈ $1.61 Billion	CN¥1.20 Billion ≈ $175.82 Million	0.109x	+55.00%
2021-12-31	CN¥10.00 Billion ≈ $1.46 Billion	CN¥705.28 Million ≈ $103.20 Million	0.071x	+384.76%
2020-12-31	CN¥7.85 Billion ≈ $1.15 Billion	CN¥114.19 Million ≈ $16.71 Million	0.015x	+32.94%
2019-12-31	CN¥5.67 Billion ≈ $829.11 Million	CN¥62.02 Million ≈ $9.08 Million	0.011x	+188.30%
2018-12-31	CN¥5.26 Billion ≈ $770.02 Million	CN¥-65.23 Million ≈ $-9.54 Million	-0.012x	-335.34%
2017-12-31	CN¥3.56 Billion ≈ $520.57 Million	CN¥-10.13 Million ≈ $-1.48 Million	-0.003x	+88.84%
2016-12-31	CN¥3.52 Billion ≈ $515.62 Million	CN¥-89.94 Million ≈ $-13.16 Million	-0.026x	-11.19%
2015-12-31	CN¥3.02 Billion ≈ $442.47 Million	CN¥-69.41 Million ≈ $-10.16 Million	-0.023x	-11.83%
2014-12-31	CN¥3.21 Billion ≈ $470.01 Million	CN¥-65.93 Million ≈ $-9.65 Million	-0.021x	+50.45%
2013-12-31	CN¥2.94 Billion ≈ $429.99 Million	CN¥-121.73 Million ≈ $-17.81 Million	-0.041x	-267.52%
2012-12-31	CN¥3.17 Billion ≈ $463.81 Million	CN¥78.38 Million ≈ $11.47 Million	0.025x	-27.05%
2011-12-31	CN¥2.71 Billion ≈ $397.06 Million	CN¥91.98 Million ≈ $13.46 Million	0.034x	-0.28%
2010-12-31	CN¥2.55 Billion ≈ $373.28 Million	CN¥86.71 Million ≈ $12.69 Million	0.034x	-92.77%
2009-12-31	CN¥174.69 Million ≈ $25.56 Million	CN¥82.18 Million ≈ $12.03 Million	0.470x	+912.58%
2008-12-31	CN¥98.36 Million ≈ $14.39 Million	CN¥-5.69 Million ≈ $-833.30K	-0.058x	-103.21%
2007-12-31	CN¥17.66 Million ≈ $2.58 Million	CN¥31.85 Million ≈ $4.66 Million	1.804x	--

About Walvax BioTech

SHE:300142 China Drug Manufacturers - Specialty & Generic

Market Cap

$2.79 Billion

CN¥19.10 Billion CNY

Market Cap Rank

#5045 Global

#842 in China

Share Price

CN¥11.94

Change (1 day)

-9.95%

52-Week Range

CN¥10.91 - CN¥16.00

All Time High

CN¥93.63